Ashland agrees to obtain ISP Ashland Inc. and International Specialty Items Inc. today announced that Ashland has agreed to acquire privately owned ISP, a worldwide specialty chemical manufacturer of innovative functional systems and ingredients get . Under the terms of the stock purchase agreement, Ashland can pay approximately $3.2 billion for the continuing business in an all-cash transaction. At closing, ISP’s advanced item portfolio will expand Ashland’s position in high-growth marketplaces such as personal treatment, pharmaceutical and energy. For the 12 a few months ended March 31, 2011, ISP generated product sales of approximately $1.6 billion and earnings before interest, taxes, depreciation and amortization of around $360 million.
Ascend Biopharmaceuticals reviews favourable results from TG1042 Stage 2 study for CBCL treatment Ascend Biopharmaceuticals, a Melbourne-based immunotherapy firm, has today announced the publication of a report utilising TG1042 for the treatment of Cutaneous B-Cell Lymphoma , in the journal PLOS One particular. Ascend Biopharmaceuticals entered into a special world-wide license contract with Transgene in July of 2013 to build up TG1042 as an immunotherapeutic injection for multiple cancers including Cutaneous B-Cell Lymphoma, CBCL . Ascend plans to sponsor and commence clinical research with TG1042 in Basal Cell Carcinoma later in 2014. Related StoriesLiposomal sizing and the Coulter basic principle: an interview with Professor Melvin E. An interview with Professor Lesley JonesViewRay obtains Korean regulatory acceptance for MRI-guided radiation therapy system The report information an open label, multi-centre trial conducted by Transgene involving 13 CBCL sufferers injected directly with TG1042 into their cancers.